Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-6450 in treatment-naïve chronic HCV
NCT02116543Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- May 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) comparing TD-6450 with Placebo (2 arms). Primary endpoint: Adverse Events at 28 Days. Started May 2014; status: completed.
02
Drugs
TD-6450
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02116543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116543.